Low-Debt Pharmaceutical Stock Falls 9% After Company Discloses Customs Department Investigation Against Senior Official

On Monday, Indian benchmark indices traded higher in early trade. As of the latest available trade, the Nifty 50 index was up 147.55 points, or 0.61 per cent, at 24,418.40. Despite the positive market sentiment, Supriya Lifescience share price declined 9.48 per cent to Rs 886.10 after the company informed the exchanges about judicial proceedings involving one of its senior officials.

Supriya Lifescience Discloses Judicial Proceedings

Supriya Lifescience informed the stock exchanges that an investigation has been initiated against Mr. Sreekant Sreedharan, General Manager – Sales & Marketing, by the Special Investigation and Intelligence Branch of the Customs Department.

According to the disclosure, the official has been placed under judicial custody until July 17, 2026, following proceedings initiated on July 3, 2026. The company stated that the disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investigation Relates to Single Export Transaction

As per the company's filing, the proceedings have been initiated under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, in connection with an alleged procedural lapse involving a single export transaction of an identified product. The company clarified that the matter pertains to the concerned employee and is currently before the competent court.

Supriya Lifescience Says No Material Operational Impact Expected

Supriya Lifescience stated that, based on the information currently available, the proceedings are not expected to have any material impact on the company's operations, financial position or corporate governance.

The company added that it is evaluating the legal implications, obtaining appropriate legal advice and will make further disclosures to the stock exchanges if there are any material developments in accordance with applicable regulations.
Also Read - Diamond Power Infrastructure Share Price Hits 10% Up; Here's Why

About Supriya Lifescience

Supriya Lifescience Ltd is an Indian pharmaceutical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and specialty chemicals. The company supplies products to regulated and semi-regulated markets across the globe, serving pharmaceutical manufacturers in multiple therapeutic segments.

The company has a diversified portfolio of APIs catering to antihistamines, anaesthetics, vitamins, anti-allergic and other therapeutic categories. It exports its products to customers across North America, Europe, Asia, Latin America and other international markets.

What are your thoughts on Supriya Lifescience's clarification regarding the ongoing investigation? Share your views in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.